Tag Archives: WRD

Top 5 Safest Stocks To Buy For 2019

U.S. home prices are on a roll. And as we head into the New Year, I am expecting another record year for home prices in 2018. Today, I am going to reveal the safest, easiest and most profitable way to benefit from this trend.

Fueled by record-low interest rates and housing inventories, home prices in the United States hit another all-time high in 2017.

The S&P CoreLogic Case-Shiller 20-City Composite Home Price NSA (SPCS20) Index measures the value of residential real estate in 20 major U.S. metropolitan areas, including New York, Los Angeles, Seattle and Chicago. The most recent update showed that the index expanded 6.1% to 203 in August, breaking the previous all-time high of 198 from July of 2007. Take a look below.

SPCS20 Index Level Since July 2007

Looking forward, I am expecting another record year. Not only will interest rates remain relatively low, but I see no short-term solution to historically low housing inventories.

Top 5 Safest Stocks To Buy For 2019: Microvision Inc.(MVIS)

Advisors’ Opinion:

  • [By Max Byerly]

    IMPINJ (NASDAQ: PI) and MicroVision (NASDAQ:MVIS) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Microvision (MVIS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Microvision (MVIS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Safest Stocks To Buy For 2019: Potlatch Corporation(PCH)

Advisors’ Opinion:

  • [By Logan Wallace]

    Itau Unibanco Holding S.A. bought a new position in Potlatchdeltic Corp (NASDAQ:PCH) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,644 shares of the real estate investment trust’s stock, valued at approximately $236,000.

  • [By Stephan Byrd]

    Teachers Insurance & Annuity Association of America bought a new position in PotlatchDeltic (NASDAQ:PCH) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 78,505 shares of the real estate investment trust’s stock, valued at approximately $4,086,000. Teachers Insurance & Annuity Association of America owned approximately 0.19% of PotlatchDeltic at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on PotlatchDeltic (PCH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Potlatchdeltic (PCH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Safest Stocks To Buy For 2019: H&R Block, Inc.(HRB)

Advisors’ Opinion:

  • [By Chris Lange]

    H&R Block, Inc. (NYSE: HRB) released fiscal fourth quarter financial results after markets closed Tuesday. The company reported $5.43 in earnings per share (EPS) and $2.39 billion in revenue compared with consensus estimates that called for $5.27 in EPS and $2.34 billion in revenue. The same period last year had $3.76 in EPS and $2.33 billion in revenue.

  • [By Paul Ausick]

    H&R Block Inc. (NYSE: HRB) traded down about 1.2% Tuesday and posted a new 52-week low of $23.28 after closing Monday at $23.55. The stock’s 52-week high is $31.80. Volume totaled about 3.1 million, about a third higher than the daily average of around  3.2 million. The company had no specific news. Shares have turned around and are headed for a gain of about 1.4% at the closing bell.

  • [By Joseph Griffin]

    TheStreet upgraded shares of H & R Block (NYSE:HRB) from a c+ rating to a b rating in a report released on Tuesday.

    Other equities research analysts have also issued research reports about the company. Barrington Research lowered their price objective on H & R Block from $32.00 to $27.00 and set an outperform rating for the company in a research note on Thursday. ValuEngine downgraded H & R Block from a sell rating to a strong sell rating in a report on Wednesday. Morgan Stanley reaffirmed an equal weight rating and set a $28.00 target price (up previously from $27.00) on shares of H & R Block in a report on Wednesday, March 7th. BMO Capital Markets reduced their target price on H & R Block from $29.00 to $25.00 and set a market perform rating on the stock in a report on Wednesday. Finally, Zacks Investment Research downgraded H & R Block from a strong-buy rating to a hold rating in a report on Tuesday, March 27th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the stock. H & R Block presently has a consensus rating of Hold and a consensus price target of $26.21.

  • [By Billy Duberstein]

    Nationwide is also the second non-bank partner that has chosen to work with Bank of the Internet. The other is H&R Block (NYSE:HRB), which sold deposits to Bank of the Internet in 2015 and still works closely with BOFI on Refund Advance Loans. In fact, BOFI management also announced a renewal of its agreement with H&R Block on the recent call.

Top 5 Safest Stocks To Buy For 2019: WildHorse Resource Development Corporation (WRD)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Wildhorse Resource Development Corp (NYSE:WRD) shares dropped 5.3% on Monday . The stock traded as low as $18.40 and last traded at $18.66. Approximately 1,428,160 shares changed hands during mid-day trading, an increase of 28% from the average daily volume of 1,115,212 shares. The stock had previously closed at $19.71.

  • [By Logan Wallace]

    Wildhorse Resource Development Corp (NYSE:WRD) – Equities research analysts at Capital One Financial lowered their FY2018 earnings per share estimates for Wildhorse Resource Development in a research note issued to investors on Monday, August 20th. Capital One Financial analyst B. Velie now forecasts that the oil and natural gas company will post earnings of $1.59 per share for the year, down from their previous estimate of $1.87. Capital One Financial also issued estimates for Wildhorse Resource Development’s Q4 2018 earnings at $0.39 EPS and FY2019 earnings at $2.07 EPS.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on WildHorse Resource Development (WRD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Safest Stocks To Buy For 2019: Keryx Biopharmaceuticals, Inc.(KERX)

Advisors’ Opinion:

  • [By Shane Hupp]

    Keryx Biopharmaceuticals (NASDAQ:KERX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Thursday. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 174.39% from the stock’s current price.

  • [By Logan Wallace]

    Keryx Biopharmaceuticals (NASDAQ:KERX) has been assigned an average rating of “Hold” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $6.00.

  • [By Ethan Ryder]

    Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). equities research analysts expect that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current fiscal year.

  • [By Maxx Chatsko]

    Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) dropped nearly 20% last month, according to data from S&P Global Market Intelligence. The pharma company announced second-quarter and first-half 2018 results that included disappointing sales revenue for its only drug, Auryxia. As a result, sales lagged behind consensus estimates despite delivering strong year-over-year growth.

  • [By Stephan Byrd]

    Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) have received a consensus rating of “Hold” from the eight brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $6.00.

Best Undervalued Stocks To Invest In 2019

A quick note: With the 280+ comments I received on my piece published over the weekend about selling a portion of your Apple (NASDAQ:AAPL) stock, I wanted to further clarify my position as the context is important in reading this piece. Unfortunately, many I fear read the title and glossed over the article before commenting, albeit insightful and informative commentary.

My main thesis was: generate a handsome profit by selling a portion (1% up to whatever you are comfortable with) of your current Apple position, because with the current Q1 numbers and future uncertainty in the hardware world, there are more undervalued stocks out there to “seek alpha.”

Unfortunately the title, “Consider Selling a Portion of Your Apple Stock to Capture Gains and Reinvest in Undervalued Sectors for Higher Probability of Alpha” – was not fit to print. And because I’m all about equal opportunity, I’ve written a strategy to make money off naysayers like me! Now onto your regularly scheduled programming

Best Undervalued Stocks To Invest In 2019: Marsh & McLennan Companies, Inc.(MMC)

Advisors’ Opinion:

  • [By Reuters]

    Wendy Maeda/The Boston Globe via Getty Images
    NEW YORK — Walgreen is moving 120,000 employees to a private health insurance exchange from coverage provided directly from carriers, the company will announce Wednesday.
    The pharmacy chain will join 17 other large employers on the Aon Hewitt Corporate Health Exchange as part of a growing movement to offer employees fixed dollar amounts to purchase their own plans on such exchanges.
    The end-cost to employees depends on the plan chosen, but they typically get more options than under traditional arrangements. Private exchanges mimic the coverage mandated as part of the Affordable Care Act. Enrollment in the public exchanges starts Oct. 1.
    “What happens to employer contributions over time? Will they put in as much as they put in the past? These are unanswered questions but potential negatives,” says Paul Fronstin, a senior research associate with the Employee Benefit Research Institute. The benefit to Walgreen and other employers is unknown at this point, as their cost-savings aren’t clear.
    Of the 180,000 Walgreen (WAG) employees eligible for health care insurance, 120,000 opted for coverage for themselves and 40,000 family members. Another 60,000 employees, many of them working part-time, weren’t eligible for health insurance.
    Aon Hewitt (AON) says other participants in its program include retailer Sears Holding (SHLD) and Darden Restaurants (DRI). These new additions raise enrollment to 330,000 from 100,000 last year, and Aon Hewitt estimates enrollment will jump to 600,000 next year, a fivefold increase from 2012.
    By 2017, nearly 20 percent of employees nationwide could get their health insurance through a private exchange, according to Accenture Research (ACN). A recent report by the National Business Group on Health said that 30 percent of large employers are considering moving active employees to exchanges by 2015.

    Other major providers of private exchanges include Mercer, a division of Marsh & Mc

Best Undervalued Stocks To Invest In 2019: WildHorse Resource Development Corporation (WRD)

Advisors’ Opinion:

  • [By Paul Ausick]

    WildHorse Resource Development Corp. (NYSE: WRD) raised $413 million on the sale of $27.5 million at $15 per share, well below the expected range of $19 to $21. Shares popped just 0.4% for the day and closed the week down 0.9%.

Best Undervalued Stocks To Invest In 2019: Plantronics Inc.(PLT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Plantronics Inc (NYSE: PLT) were down 25 percent to $33.36. Plantronics reported better-than-expected third-quarter earnings, but the company’s revenue missed analysts’ expectations. The company announced a new 1 million share buyback plan and issued a weak earnings forecast for the fourth quarter.

  • [By Joseph Griffin]

    TRADEMARK VIOLATION NOTICE: “Brian S. Dexheimer Sells 500 Shares of Plantronics (PLT) Stock” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at www.tickerreport.com/banking-finance/3355123/brian-s-dexheimer-sells-500-shares-of-plantronics-plt-stock.html.

Best Undervalued Stocks To Invest In 2019: Caleres, Inc.(CAL)

Advisors’ Opinion:

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By Lisa Levin]

    Shares of Caleres Inc (NYSE: CAL) got a boost, shooting up 12 percent to $31.99 after the company posted upbeat Q3 earnings.

    QAD Inc. (NASDAQ: QADA) shares were also up, gaining 14 percent to $29.44 after the company posted strong Q3 results.

Best Undervalued Stocks To Invest In 2019: VEXIM EUR0.10 (VXMFF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    French medical device maker Vexim (OTC:VXMFF) contracted with an unnamed China lab to begin China registration studies for its vertebral fracture repair device, SpineJack庐. Vexim recently was granted patents for the device in China and Japan. SpineJack is an implant designed to repair a fractured vertebra and restore spinal cord balance. The 30 minute procedure is useful in 95% of vertebral fractures, according to Vexim. SpineJack was CE marked for EU use in 2010 and now is indicated for trauma and other vertebral fractures.

Top Undervalued Stocks To Own Right Now

Photo courtesy of Pexels

Welcome to The Salary Chronicles, where we’re bringing transparency to negotiation and salaries, one story at a time. We ask women to share their experiences negotiating their salary and what their advice is for others doing the same. We share these stories anonymously so they feel comfortable speaking as openly and as freely as possible.

This week we’re speaking with a woman prioritized the benefit of telecommuting so much, she almost undervalued herself in her job search. 

Title: Director of Product Strategy

Location: Florida

Original salary: $103K

New salary: $118K + 15% bonus

What was the situation?

I had been working at a company for a couple of years, and while I really enjoyed it, the commute was brutal. I commuted 3 hours each day and that left me with a really limited amount of time to spend with my kids. I was a strong employee so the company let me experiment with working from home, but I knew it wasn’t a long term solution. I felt disconnected from my co-workers in the office and had trouble actively participating in meetings when I called in. I knew that if I wanted to make my telecommuting permanent while not impeding my career progression, I needed to find a company that had a virtual workforce, rather than try to be effective as the one employee who worked from home.

Top Undervalued Stocks To Own Right Now: WildHorse Resource Development Corporation (WRD)

Advisors’ Opinion:

  • [By Paul Ausick]

    WildHorse Resource Development Corp. (NYSE: WRD) raised $413 million on the sale of $27.5 million at $15 per share, well below the expected range of $19 to $21. Shares popped just 0.4% for the day and closed the week down 0.9%.

Top Undervalued Stocks To Own Right Now: Staples, Inc.(SPLS)

Advisors’ Opinion:

  • [By Rich Duprey]

    A few years ago, office-supplies retailerStaples(NASDAQ:SPLS)and electronics store RadioShack thought they could benefit from the e-tailer’s sales prowess. Although they were losing sales regularly to Amazon, they thoughtplacing lockersin their stores could also result in the sale of an extra ream of paper or a few capacitors and potentiometers. Instead what they found was customers were simply buying their paper, ink cartridges, and electronic gadgets on Amazon and picking them up in their stores. After just a year, Staples and RadioShack abruptly ended the program.

  • [By Lisa Levin]

    Shares of Staples, Inc. (NASDAQ: SPLS) got a boost, shooting up 7 percent to $9.25 on chatter that the company is targeted for an acquisition. Sycamore Partners, a private equity giant, is reportedly in advanced talks to acquire the office supply retailer, Reuters reported. The deal could value Staples at more than $6 billion, a premium to Staples' valuation of $5.60 billion as of Wednesday's market close.

  • [By Casey Wilson]

    The company was set to merge with its last remaining rival, Staples Inc. (Nasdaq: SPLS), this year, but was denied by a federal judge on May 10 because of antitrust concerns.

  • [By Ben Levisohn]

    Staples (SPLS) soared to the top of the S&P 500 today on reports that the office-supplies retailer was considering selling itself.

    Agence France-Presse/Getty Images

    Staples gained 9.8% to $9.51 today, while the S&P 500 ticked up 0.1% to 2,360.16.

    CFRA’s Efraim Levy doesn’t see a “natural buyer” for Staples but remain Buy rated anyway:

    Shares are higher on an unconfirmed WSJ report that SPLS is looking at the possible sale of the company. Our fundamentally valued 12-month target of $11, applies a below historical average P/E of 12.1X our FY 18 EPS estimate, given office industry challenges. Our target has 11% upside, plus a 5.5% yield. We don’t see a natural buyer for a large physical store office supply presence, although an activist/private-equity buyer is a possibility. To make an acquisition worthwhile, a buyer would have to be more aggressive in cost cutting and use of cash flow than SPLS’s existing plan.

    Staples’ market capitalization rose to $6.2 billion today from $5.7 billion yesterday. It reported a net loss of $459 million on sales of $18.2 billion in fiscal 2017.

Top Undervalued Stocks To Own Right Now: GTx Inc.(GTXI)

Advisors’ Opinion:

  • [By Roberto Pedone]

    One biopharmaceutical player that’s rapidly moving within range of triggering a major breakout trade is GTx (GTXI), which is dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical condition. This stock has been hammered by the bears so far in 2013, with shares off sharply by 53%.

    If you look at the chart for GTx, you’ll notice that this stock recently gapped down sharply from over $4 to below $1.50 a share with heavy downside volume. Following that gap down, shares of GTXI have rebounded sharply and started to uptrend, with the stock moving higher from its low of $1.31 to its recent high of $1.96 a share. During that move, shares of GTXI have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GTXI within range of triggering a major breakout trade.

    Traders should now look for long-biased trades in GTXI if it manages to break out above some near-term overhead resistance at $1.96 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.35 million shares. If that breakout triggers soon, then GTXI will set up to re-fill some of its previous gap down zone from August that started just above $4 a share. Some possible upside targets if GTXI gets into that gap with volume are $2.50 to $3 a share, or possibly even $3.50 a share.

    Traders can look to buy GTXI off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.50 a share. One can also buy GTXI off strength once it takes out $1.96 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

financial markets

June 22, 2017: Here are four stocks trading with heavy volume among 106 equities making new 52-week lows in Thursday’s session. On the NYSE, advancers led decliners by nearly 3 to 2 and on the Nasdaq, advancers led decliners by about the same ratio.

The Hain Celestial Group Inc. (NASDAQ: HAIN) posted a new 52-week low of $31.70 on Thursday, down about 4.4% compared with Wednesday’s closing price of $33.16. The stock’s 52-week high is $56.99. Volume totaled more than 12.5 million shares, about 10 times the daily average of around 1.2 million. The organic food company said this morning that an accounting review has shown that the company does not need to change its accounting practices. Shares turned positive later in the day and are on track to close up about 1%.

DDR Corp. (NYSE: DDR) dropped about 3.2% Thursday to post a new 52-week low of $8.11 after closing at $8.38 on Wednesday. The stock’s 52-week high is $19.92. Volume of nearly 12 million was about 40% higher than the daily average. The company had no specific news.

financial markets: The Michaels Companies, Inc.(MIK)

Advisors’ Opinion:

  • [By Laurie Kulikowski]

    We rate MICHAELS COS INC as a Sell with a ratings score of D+. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been weak operating cash flow. 

  • [By Jim Cramer]

    After a year of stock price fluctuations, the net result is that MIK’s price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don’t lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.

     

  • [By Jim Cramer]

    The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Specialty Retail industry average. The net income increased by 20.0% when compared to the same quarter one year prior, going from $64.00 million to $76.80 million.

     

  • [By WWW.THESTREET.COM]

    Earnings of note in the coming week include Analogic (ALOG) and Ascena Retail (ASNA) on Monday; Bojangles (BOJA) , H&R Block (HRB) , and Dick’s Sporting Goods (DKS) , Michaels (MIK) , and Urban Outfitters (URBN) on Tuesday; Ciena (CIEN) , Bankrate (RATE) , Express (EXPR) , Vera Bradley (VRA) , and Bob Evans Farms (BOBE) on Wednesday; El Pollo Loco (LOCO) , Hugo Boss (BOSSY) , Party City (PRTY) , Signet Jewelers (SIG) , and Verifone Systems (PAY) on Thursday; and Kirkland’s (KIRK) , and Vail Resorts (MTN) on Friday.

  • [By JPMorgan]

    MIK’s results over the past year point to the company’s success in improving merchandising, marketing, and in-store execution plus the benefits of having a functioning e-commerce website. We believe part of the challenge for the bears is both a lack of appreciation for the category as well as missing the historical context of how leadership has evolved. Indeed, the difference in focus on "the front end" under CEO Chuck Rubin (who arrived in 2013) vs. a more process-oriented and margin-focused CEO prior to his arrival left a lot of impactful, low hanging fruit opportunities. Finally, while we acknowledge that longer term the sustainable comp is lower than the recent ~4% underlying trend, we point to the low volatility of sales, high cash generative nature of the business, barriers to entry (e.g., high SKU density, low inventory turns, lack of brands), and MIK’s market leadership as reasons why the multiple has the potential to expand over time (a la AZO). Balance sheet de-levering should also make the PE look increasingly cheap over time and transfer cash/value to equity holders. 

  • [By Jim Cramer]

    42.37% is the gross profit margin for MICHAELS COS INC which we consider to be strong. Regardless of MIK’s high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 6.57% trails the industry average.

    MICHAELS COS INC has improved earnings per share by 19.4% in the most recent quarter compared to the same quarter a year ago. This year, the market expects an improvement in earnings ($1.70 versus $1.04).

     

financial markets: Sage Therapeutics, Inc.(SAGE)

Advisors’ Opinion:

  • [By Lisa Levin]

    SAGE Therapeutics Inc (NASDAQ: SAGE) shares shot up 73 percent to $159.39 after the company disclosed that Phase 2 trial of SAGE-217 met its primary endpoint.

  • [By WWW.THESTREET.COM]

    Position: Long GLD small, bonds, SDS; short TLT small, SPY small .

  • [By Chris Lange]

    Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) saw an incredible gain on Thursday after the firm announced positive top-line results from its midstage trial. Specifically, the firm reported results from its Phase 2 trial of Sage-217 for the treatment of moderate to severe major depressive disorder (MDD).

  • [By WWW.THESTREET.COM]

    The Good

    The market remains resistant (Rs over Ss and Ns). Brokerages, banks and insurance companies continue their league-leading strength. The Russell 2000 Index is up for the 15th consecutive day. Retail extends yesterday’s strength. Nordstrom (JWN) , Macy’s (M) , Best Buy (BBY) , Target (TGT) , Walmart (WMT) , Foot Locker (FL) and JCPenney (JCP) are strong. First day down for Amazon (AMZN) . Agricultural commodities are lackluster, but soybeans are up another up $0.05 today, up substantially for three days in a row. Speculative biotech (Sage (SAGE) , FibroGen (FGEN) , Acadia Pharmaceuticals (ACAD) and Aerie Pharmaceuticals  (AERI) ) stronger after recent weakness. Ag equipment up big time after the Deere (DE) beat.

    The Bad

financial markets: WildHorse Resource Development Corporation (WRD)

Advisors’ Opinion:

  • [By Paul Ausick]

    WildHorse Resource Development Corp. (NYSE: WRD) raised $413 million on the sale of $27.5 million at $15 per share, well below the expected range of $19 to $21. Shares popped just 0.4% for the day and closed the week down 0.9%.

financial markets: VEXIM EUR0.10 (VXMFF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    French medical device maker Vexim (OTC:VXMFF) contracted with an unnamed China lab to begin China registration studies for its vertebral fracture repair device, SpineJack庐. Vexim recently was granted patents for the device in China and Japan. SpineJack is an implant designed to repair a fractured vertebra and restore spinal cord balance. The 30 minute procedure is useful in 95% of vertebral fractures, according to Vexim. SpineJack was CE marked for EU use in 2010 and now is indicated for trauma and other vertebral fractures.

financial markets: Xcel Energy Inc.(XEL)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Jefferies announced on Wednesday that it has raised its rating on Xcel Energy Inc (XEL).

    The firm has upgraded XEL from “Hold” to “Buy,” and has raised the company’s price target from $31 to $32.50. This new price target suggests a 15% upside from the stock’s current price of $27.72.

    Analyst Paul B. Fremont commented: “The stock is currently trading at an 8% P/E discount to our 2015E group average multiple.”

    “Despite a difficult political environment in Minnesota the company was able to achieve a reasonable outcome in its NSP-Minnesota rate case,” the analyst added.

    Looking forward, the firm has increased its FY2014 outlook from $1.95 to $2.00 per share.

    Xcel Energy shares were mostly flat during pre-market trading Wednesday. The stock has been mostly flat YTD.

financial markets: Chiasma, Inc.(CHMA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Chiasma Inc (NASDAQ: CHMA) was down, falling around 13 percent to $9.51 ahead of the U.S. Food and Drug Administration’s decision on Friday to approve or reject the company’s therapy. The status of its oral treatment for acromegaly, a capsule known as Mycapssa, will be in focus on Friday. The Street’s biotechnology expert Adam Feuerstein stated that an investor source believes the FDA will reject Chiasma’s capsules because data from a single-arm study failed to demonstrate a clinically meaningful benefit among patients.

Best Safest Stocks To Own Right Now

For some, Apple’s (NASDAQ:AAPL) WWDC keynote event went liked they hoped, with the company introducing some exciting new products or technologies that hit all the sweet spots in today’s dramatically reshaped tech environment. Augmented reality, artificial intelligence, smart speakers, digital assistants, convolutional neural networks, machine learning and computer vision were all mentioned in some way, shape or form during the address.

For others, the event went like they expected, with Apple delivering on virtually all the big rumors they were “supposed” to meet: updated Macs and iPads, a platform for building AR apps on iOS devices, and a Siri-driven smart speaker.

For me, the event was a satisfying affirmation that the company has not fallen behind its many competitors and is working on products and platforms that take advantage of the most interesting and potentially exciting new technologies across hardware, software and services that we’ve seen for some time. In addition, they laid the groundwork for ongoing advancements in overall contextual intelligence, which will likely be a critical distinction across digital assistants for some time to come.

Best Safest Stocks To Own Right Now: WildHorse Resource Development Corporation (WRD)

Advisors’ Opinion:

  • [By Paul Ausick]

    WildHorse Resource Development Corp. (NYSE: WRD) raised $413 million on the sale of $27.5 million at $15 per share, well below the expected range of $19 to $21. Shares popped just 0.4% for the day and closed the week down 0.9%.

Best Safest Stocks To Own Right Now: Applied Micro Circuits Corporation(AMCC)

Advisors’ Opinion:

  • [By Piyush Arora]

    AMD, along with other server-grade chip manufacturers such as Qualcomm (NSDQ:QCOM), Cavium (NSDQ:CAVM) and AMCC (NSDQ:AMCC), operates in the remaining minuscule 0.8% of the market. So, each of the aforementioned companies operate with a practically non-existent market share, compared to Intels shipments of course. This also means that these firms (AMD, Qualcomm etc.) have plenty of room to grow. This would be subject to good product releases of course, but at least this way, the law of large numbers isnt working against them.

Best Safest Stocks To Own Right Now: Attunity Ltd.(ATTU)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, ourUnder the Radar Moversnewsletter suggested small cap Big Data stock Attunity Ltd (NASDAQ: ATTU) as a short trade:

    “Attunity has also been on the watchlist for a while. It’s a straight-up momentum play Well, straight down momentum play. We’re just getting on board the train after a brief lull in the downtrend. This one isn’t going to be a monster-sized winner, but it’s a high-odds, low-risk trade.”

Best Safest Stocks To Own Right Now: Powell Industries Inc.(POWL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Powell Industries, Inc. (NASDAQ: POWL) were down 14 percent to $40.06. Powell Industries reported Q4 adjusted earnings of $0.54 per share on sales of $129.8 million.

Best Safest Stocks To Own Right Now: Finisar Corporation(FNSR)

Advisors’ Opinion:

  • [By Leo Sun]

    Shares of fiber optic components maker Finisar (NASDAQ:FNSR) fell 17% in April due to a big third-quarter miss in mid-March. Its revenue rose 23% annually to $380.6 million, but that missed expectations by $9 million. Earnings rose136% to $0.59 per share, but that also missed estimates by three cents. Finisar’s top and bottom line guidance for the fourth quarter (16% sales growth and 83% earnings growth at the midpoints) also came in below Wall Street estimates.

  • [By Lisa Levin]

    Finisar Corporation (NASDAQ: FNSR) shares dropped 21 percent to $27.46 after the company reported weaker-than-expected results for its third quarter and issued disappointing forecast for the current quarter.

  • [By Anders Bylund]

    Shares of Finisar (NASDAQ:FNSR) rose 13.2% in February 2017, according to data from S&P Global Market Intelligence.

    So what

    The bulk of Finisar’s February surge started when chief rival Lumentum (NASDAQ:LITE) delivered a strong earnings surprise, followed by several rosy analyst reviews. Lumentum’s solid results led investors to optimistic conclusions about the many target markets these two companies have in common, and Finisar’s gains nearly matched Lumentum’s post-earnings surge.